共 15 条
[1]
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study[J] . Mohamed Hassanein,Wasim Hanif,Waqar Malik,Ali Kamal,Parnia Geransar,Nicola Lister,Chris Andrews,Anthony Barnett.Current Medical Research & Opinion . 2011 (7)
[2]
Diabetes and Ramadan: An update On use of glycemic therapies during fasting[J] . Mohamed Ahmed,Tarig Abdu.Annals of Saudi Medicine . 2011 (4)
[4]
Recommendations for Management of Diabetes During Ramadan
[J].
DIABETES CARE,
2010, 33 (08)
:1895-1902
[5]
Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study[J] . D. R.Matthews,S.Dejager,B.Ahren,V.Fonseca,E.Ferrannini,A.Couturier,J. E.Foley,B.Zinman.Diabetes, Obesity and Metabolism . 2010 (9)
[6]
Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience[J] . James Foley.Vascular Health and Risk Management . 2010 (defa)
[8]
Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-na?ve Patients with Type 2 Diabetes[J] . J. E. Foley,S. Sreenan.Horm Metab Res . 2009 (12)
[10]
Efficacy and tolerability of vildagliptin in drug‐na?ve patients with type 2 diabetes and mild hyperglycaemia*[J] . W. A.Scherbaum,A.Schweizer,A.Mari,P. M.Nilsson,G.Lalanne,S.Jauffret,J. E.Foley.Diabetes, Obesity and Metabolism . 2008 (8)